Adaptimmune Therapeutics Valuation

ADAP Stock  USD 0.58  0.01  1.69%   
Adaptimmune Therapeutics is undervalued. Adaptimmune Therapeutics shows a prevailing Real Value of $0.99 per share. The current price of the firm is $0.58. Our model approximates the value of Adaptimmune Therapeutics from analyzing the firm fundamentals such as profit margin of (0.51) %, and Return On Equity of -0.65 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Adaptimmune Therapeutics' valuation include:
Price Book
1.8551
Enterprise Value
36.8 M
Enterprise Value Ebitda
(1.71)
Price Sales
1.049
Enterprise Value Revenue
0.2102
Undervalued
Today
0.58
Please note that Adaptimmune Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Adaptimmune Therapeutics is based on 3 months time horizon. Increasing Adaptimmune Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Adaptimmune Therapeutics' intrinsic value may or may not be the same as its current market price of 0.58, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.58 Real  0.99 Target  2.27 Hype  0.58
The intrinsic value of Adaptimmune Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adaptimmune Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.99
Real Value
6.09
Upside
Estimating the potential upside or downside of Adaptimmune Therapeutics Plc helps investors to forecast how Adaptimmune stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adaptimmune Therapeutics more accurately as focusing exclusively on Adaptimmune Therapeutics' fundamentals will not take into account other important factors:
Earnings
Estimates (0)
LowProjectedHigh
-0.05-0.04-0.01
Details
Hype
Prediction
LowEstimatedHigh
0.030.585.68
Details
9 Analysts
Consensus
LowTarget PriceHigh
2.062.272.52
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adaptimmune Therapeutics' intrinsic value based on its ongoing forecasts of Adaptimmune Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adaptimmune Therapeutics' closest peers.

Adaptimmune Therapeutics Cash

112.8 Million

Adaptimmune Valuation Trend

Adaptimmune Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Adaptimmune Therapeutics' financial worth over time. Using both Adaptimmune Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.

Adaptimmune Therapeutics Total Value Analysis

Adaptimmune Therapeutics Plc is presently forecasted to have valuation of 36.79 M with market capitalization of 148.39 M, debt of 25.23 M, and cash on hands of 199.67 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adaptimmune Therapeutics fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
36.79 M
148.39 M
25.23 M
199.67 M

Adaptimmune Therapeutics Investor Information

About 60.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adaptimmune Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.11. The entity recorded a loss per share of 0.17. The firm last dividend was issued on the 30th of March 2018. Based on the key indicators related to Adaptimmune Therapeutics' liquidity, profitability, solvency, and operating efficiency, Adaptimmune Therapeutics Plc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.

Adaptimmune Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adaptimmune Therapeutics has an asset utilization ratio of 21.33 percent. This connotes that the Company is making $0.21 for each dollar of assets. An increasing asset utilization means that Adaptimmune Therapeutics Plc is more efficient with each dollar of assets it utilizes for everyday operations.
 
Yuan Drop
 
Covid

Adaptimmune Therapeutics Ownership Allocation

Adaptimmune Therapeutics holds a total of 255.88 Million outstanding shares. Over half of Adaptimmune Therapeutics' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Adaptimmune Therapeutics Profitability Analysis

The company reported the previous year's revenue of 60.28 M. Net Loss for the year was (113.87 M) with loss before overhead, payroll, taxes, and interest of (5.19 M).

About Adaptimmune Therapeutics Valuation

The stock valuation mechanism determines Adaptimmune Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Adaptimmune Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adaptimmune Therapeutics. We calculate exposure to Adaptimmune Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adaptimmune Therapeutics's related companies.
Last ReportedProjected for Next Year
Gross Profit45.4 M47.7 M
Pretax Profit Margin(2.15)(2.25)
Operating Profit Margin(2.63)(2.77)
Net Loss(2.17)(2.28)
Gross Profit Margin 0.75  0.79 

Adaptimmune Therapeutics Growth Indicators

Investing in growth stocks can be very risky. If the company such as Adaptimmune Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding201.1 M

Adaptimmune Therapeutics Current Valuation Indicators

Adaptimmune Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adaptimmune Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adaptimmune Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adaptimmune Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adaptimmune Therapeutics' worth.

Additional Tools for Adaptimmune Stock Analysis

When running Adaptimmune Therapeutics' price analysis, check to measure Adaptimmune Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptimmune Therapeutics is operating at the current time. Most of Adaptimmune Therapeutics' value examination focuses on studying past and present price action to predict the probability of Adaptimmune Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptimmune Therapeutics' price. Additionally, you may evaluate how the addition of Adaptimmune Therapeutics to your portfolios can decrease your overall portfolio volatility.